2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione | 1365036-10-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}-2,3-dihydro-1H-isoindole-1,3-dione；2-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]isoindole-1,3-dione
• CAS: 1365036-10-7
• 化学式: C₂₅H₂₄ClN₃O₂
• 分子量: 433.937
• InChiKey: LYZNQLCSRJBILT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione 在 甲胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 16.0h， 生成 N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}naphthalene-2-sulfonamide
  参考文献：
  名称：

  Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity

  摘要：

  The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-{244-(5-chloro-1H-iridol-3-y1)-1,2,3,6-tetrahydropyridin-l-yllethy1}-3-methylbenzene-l-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia.

  DOI：

  10.1021/acs.jmedchem.7b00839
• 作为产物：
  描述：

  N-(3-溴丙基)苯二胺 、 5-氯-2-甲基-3-(1,2,3,6-四氢-4-吡啶基)-1H-吲哚 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以67%的产率得到2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione
  参考文献：
  名称：

  Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity

  摘要：

  The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-{244-(5-chloro-1H-iridol-3-y1)-1,2,3,6-tetrahydropyridin-l-yllethy1}-3-methylbenzene-l-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia.

  DOI：

  10.1021/acs.jmedchem.7b00839

文献信息

• ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES
  申请人：Kolaczkowski Marcin

  公开号：US20130172365A1

  公开（公告）日：2013-07-04

  Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.

  化学式（I）的芳基磺胺衍生物及其药用盐。这些化合物可能对中枢神经系统疾病的治疗和/或预防有用。
• US8822517B2
  申请人：——

  公开号：US8822517B2

  公开（公告）日：2014-09-02
• US9120767B2
  申请人：——

  公开号：US9120767B2

  公开（公告）日：2015-09-01
• Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1<i>H</i>-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity
  作者：Adam Bucki、Monika Marcinkowska、Joanna Śniecikowska、Krzysztof Więckowski、Maciej Pawłowski、Monika Głuch-Lutwin、Anna Gryboś、Agata Siwek、Karolina Pytka、Magdalena Jastrzębska-Więsek、Anna Partyka、Anna Wesołowska、Paweł Mierzejewski、Marcin Kołaczkowski

  DOI：10.1021/acs.jmedchem.7b00839

  日期：2017.9.14

  The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-244-(5-chloro-1H-iridol-3-y1)-1,2,3,6-tetrahydropyridin-l-yllethy1}-3-methylbenzene-l-sulfonamide), exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia.